February may be the shortest month, but the HD research community has packed a lot into it. From test data that was peer-reviewed and finally published in journals, to fundamental discoveries about how brain cells are wired, to tiny bugs doing the heavy lifting in the lab, there was a lot to catch up on. This month’s article also highlights the human side of HD, reminding us that behind every data point is a human being navigating real uncertainty. Let’s dig deeper.
A theme that unifies the moon
The value of published data: One of the most important stories this month was not about success, but about making sure setbacks are properly documented so we can learn from them moving forward. The publication of the results of the VIBRANT-HD trial testing the HTT-lowering drug branapram is a reminder that science advances when we honestly explain what works, what doesn’t, and what we learn from it.
genetics is complex: Two articles this month pushed back against the idea that one number, CAG repeats, tells the whole story. Is it a specific DNA sequence? around it The details, such as their repetition and exactly how the brain cells are wired, turn out to be very important.
HD affects the whole person: February shined a much-needed spotlight on the psychological health of people living at risk for HD, bringing an eye-opening review of how even the retina and eye movements can reveal what’s going on in the brain. HD is more than just a movement disorder; it affects every aspect of your life.
HD is more than just a movement disorder; it affects every aspect of your life.
Latest information on clinical trials
Published: Oral drug branapram lowered huntingtin, but development was halted due to safety concerns
Results from the VIBRANT-HD trial testing the oral HTT-lowering drug branapram have been announced. It was officially announced in natural medicine. The positive takeaway from this trial was that branapram was effective, reducing swollen HTT levels in the spinal fluid by about 25% compared to placebo. This provided the first clear evidence that a pill can be used to lower HTT in HD patients.
The bad news was that about three-quarters of the participants showed signs of nerve damage and the trial was stopped early. This damage is largely reversible after drug discontinuation, and the knowledge gained, including the validation of NfL as an early warning safety biomarker, will continue to inform the next generation of oral HTT-lowering drugs currently in clinical trials.
HD Understanding Biology
Rescue the Worms: Separating the Good, the Bad, and the Clumpy Hunting Tin
Not all HTT protein chunks are created equal; smart new research By separating them and feeding them to microscopic insects, they determined which were more dangerous. The verdict of this study was that small, flexible clumps are highly toxic, but large, hard structures, which are often thought to be the culprits, pose no harm at all in this study.
When the researchers chemically “stapled” the small clumps to make them less flexible, the worms’ survival rates improved. This suggests that the flexibility of the clumps, rather than their size, may be the key to their toxicity. Although this is still early stage nematode science, it opens up interesting new angles. Could sequestering toxic protein clumps be a therapeutic strategy for HD?
supercomputer failure
UCLA researchers The researchers looked in three dimensions at the most vulnerable brain circuit in HD, the medium-spine neurons in the striatum, and found that these cells look different depending on their location in the brain, with different spine lengths, densities, and branching patterns. More importantly, in mice that modeled HD, these neurons were less complex and had fewer connections than in healthy mice.
This suggests that the striatum in HD may be gradually losing connections with other parts of the brain, just as the central processing core is slowly being uncoupled. Understanding exactly how this happens could open new avenues for treatments aimed at restoring or protecting these critical circuits.
Impasse: Why DNA sequence patterns matter in Huntington’s disease
The number of CAG repeats is not everything. accurate pattern The DNA sequences surrounding these repeats are very important. New study by researchers in Vancouver and Paris They tested 328 people with CAG repeats ranging from 36 to 42 and found that people lacking important breaks in repeat sequences, called the “loss of interruption” pattern, developed symptoms nearly 13 years earlier than predicted by repeat number alone and progressed about twice as fast.
Standard genetic tests count the number of CAG repeats, but variations in these sequences are often missed. This means that some people in the HD gray zone may face higher risks than the results indicate. This discovery has major implications for genetic counseling, disease prediction, and clinical trial design, and the research team also identified an entirely new sequence variant never before reported.
biomarker
Window of the Eye: Tracking HD Progression Using Ocular Biomarkers
Can a simple eye exam help track HD? Review from University of Cambridge We investigated the evidence of retinal scans and eye movement tracking as potential biomarkers. While retinal imaging has shown inconsistent results across studies and is not ready for clinical use, eye movement tracking tells a more promising story. There are measurable and progressive differences in eye movements in HD patients, including those who do not yet exhibit symptoms.
The problem is that the technology is expensive and not widely available, and research needs to become more standardized before eye tracking can be deployed as a clinical tool. However, the consistency of research results makes it one of the most attractive non-invasive biomarker candidates in the HD field to date.
Living with HD
Two worlds split: Psychological challenges for people at risk of HD
Interview-based study in Lancaster, UK After listening carefully to 12 people living at risk of HD, we found that maintaining psychological health is not a fixed state, but an active, daily effort. Participants described moving back and forth between two worlds. One defined by the reality of HD, the other a world that everyday life can exist next to, not in denial, but in a conscious and skilled balancing act.
Many also said they felt a constant sense of urgency to live fully while they still could, alongside the arduous task of protecting their identity and managing stigma from others. This study clearly demonstrates the need for better training among healthcare workers and more accessible psychological support for people at risk. Because the invisible mental burden of living with uncertainty is just as noteworthy as the physical symptoms.
People at risk and living with uncertainty every day have the right to see their experiences reflected in science and supported by the care they receive.
Looking to the future
February’s articles paint a rich picture of HD research in 2026. The field is maturing, diversifying, and increasingly adapting to the full complexity of this disease. While the next generation of oral HTT-lowering drugs continues in clinical trials, the published VIBRANT-HD data concludes its first chapter.
Emerging science about CAG sequence patterns and brain circuit connections promises to enhance our ability to predict and treat HD. Additionally, increased attention is being paid to biomarkers, from eye movements to protein aggregate structure, expanding the toolkit available to researchers and clinicians.
Most importantly, this month reminded us that HD research is not just about molecules and mechanisms. People at risk and living with uncertainty every day have the right to see their experiences reflected in science and supported by the care they receive.
summary
- VIBRANT-HD study results for Buranapuram have been announced. Although this study showed that oral HTT reduction was possible, development of this drug was discontinued due to side effects of nerve damage. These lessons will continue to inform the next generation of medicines.
- Studies in laboratory C. elegans suggest that small, flexible clumps of HTT protein are the most toxic form.
- 3D mapping of HD-vulnerable brain circuits reveals fewer connections in HD mice
- DNA sequence patterns within the CAG repeat region can accelerate the onset of symptoms by up to 13 years and double the rate of progression.
- Eye movement tracking shows promise as an early HD biomarker.
- The interview-based study highlighted the daily psychological task of living with the risk of HD and the urgent need for better support from health professionals.
Supports HDBuzz
If you value the service HDBuzz provides, please consider making a donation. We want HDBuzz to be sustainable so we can continue to report unbiased science to the HD community.
Your support allows us to ensure the continuity of our services. Nothing is expected of you, but everything is appreciated and supports what we do at HDBuzz. Please try to do what you can.